Oxcarbazepine Suspension
Product Images NDC 42806-600

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 42806-600). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Epic Pharma, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Oxcarbazepine Structural Formula (Oxcarbazepine 01)

Chemical structure of oxcarbazepine showing a central seven-membered ring with an oxygen atom double bonded, attached to two benzene rings and an amide group (CONH2) connected to a nitrogen atom in the ring.*

FDA Label Image

Figure 1: Kaplan-meier Estimates Of Exit Rate By Treatment Group (Oxcarbazepine 02)

A Kaplan-Meier survival curve chart showing exit rate over time on trial from Day 2 to Day 11 comparing two treatment groups: Oxcarbazepine (solid line) and Placebo (dotted line). The chart includes a log-rank test p-value of 0.0001, indicating statistical comparison between the groups.*

FDA Label Image

Figure 2: Kaplan-meier Estimates Of First Seizure Event Rate By Treatment Group (Oxcarbazepine 03)

A Kaplan-Meier curve chart showing seizure rate over days from first dose to first seizure. The chart compares seizure rates between two treatment groups: Oxcarbazepine and Placebo, with Oxcarbazepine represented by a solid line and Placebo by a dashed line. The x-axis shows days from first dose to first seizure, and the y-axis shows seizure rate. A p-value from a log-rank test (0.046) is included.*

FDA Label Image

Figure 3 Kaplan-meier Estimates Of Exit Rate By Treatment Group (Oxcarbazepine 04)

A Kaplan-Meier curve chart showing exit rate over time in days for two treatment groups labeled HIGH and LOW. The vertical axis represents exit rate from 0.0 to 1.0, and the horizontal axis represents time to exit up to 130 days. The LOW treatment group has a higher, rapidly increasing exit rate, while the HIGH group shows a slower increase. A log-rank test p-value of 0.0001 is noted on the graph.*

FDA Label Image

Figure 4 Kaplan-meier Estimates Of Exit Rate By Treatment Group (Oxcarbazepine 05)

A Kaplan-Meier curve displaying exit rates over time in days with two treatment groups labeled as HIGH (solid line) and LOW (dotted line). The y-axis represents exit rate ranging from 0.0 to 1.0, and the x-axis represents time to exit up to 130 days. The graph includes a log-rank test p-value of 0.0001 indicating statistical comparison between groups.*

FDA Label Image

Cap (Oxcarbazepine 06)

Packaging label image of Oxcarbazepine oral suspension, 300 mg per 5 mL. The image shows a single dose cup with measurement markings. The labeler is EPIC PHARMA, LLC. This unit-dose container is designed for precise oral administration of the medication.*

FDA Label Image

Bottle (Oxcarbazepine 07)

Oxcarbazepine oral suspension in a gray bottle with a white child-resistant cap. The bottle is unmarked with no visible labels or text. The suspension is intended for oral use, labeled under EPIC PHARMA, LLC.*

FDA Label Image

Filler (Oxcarbazepine 08)

An instructional diagram of a syringe used for oral suspension dosing. The syringe is labeled with measurement marks from 1 to 10 milliliters and parts labeled as 'Barrel' and 'Plunger' to indicate components for drawing and administering liquid medication.*

FDA Label Image

Shake (Oxcarbazepine 09)

Illustration showing a hand holding a bottle of oral suspension, shaking it manually. The image likely demonstrates the proper way to mix the contents before use.*

FDA Label Image

Insert (Oxcarbazepine 10)

An instructional illustration showing two hands opening a bottle by removing its child-resistant cap. The cap is off to the side, with an arrow indicating the direction to push the cap before twisting. The bottle is opaque and cylindrical, suggesting a liquid medication container.*

FDA Label Image

Mix (Oxcarbazepine 11)

An illustration showing a hand holding and shaking a bottle, indicating that the Oxcarbazepine 300 mg/5 mL oral suspension should be shaken before use.*

FDA Label Image

Inject (Oxcarbazepine 12)

An instructional illustration showing a hand holding a syringe-like device inserted into the neck of a bottle, with another hand steadying the bottle below. A downward arrow points to the connection, indicating how to attach or dispense liquid from the bottle using the device.*

FDA Label Image

Extract1 (Oxcarbazepine 13)

An instructional illustration showing the correct method for drawing liquid medication from a bottle into a syringe. It depicts a hand holding a syringe under an inverted bottle, with arrows indicating an up-and-down motion for filling the syringe.*

FDA Label Image

Extract1 (Oxcarbazepine 14)

An instructional illustration showing how to measure and dispense an oral suspension dose using a dosing syringe attached to a bottle. The image includes a close-up inset of the syringe with volume markings up to 10 mL, emphasizing accurate dose measurement.*

FDA Label Image

Revolve (Oxcarbazepine 15)

An instructional illustration depicting a hand holding a syringe-like measuring device that is being twisted to attach or detach from the top of a bottle. This likely demonstrates how to prepare the oral suspension dosing device for use with the medication.*

FDA Label Image

Dispense (Oxcarbazepine 17)

An instructional illustration depicting the correct administration of oral suspension medication using a syringe. The first part shows a child receiving the medication from a syringe held by an adult, and the second part shows the syringe being rinsed or filled by dripping liquid into a cup. This image demonstrates proper use and handling of an oral liquid dosage form.*

FDA Label Image

Principal Display Panel-300 mg/5 mL (Oxcarbazepine 18)

Oxcarbazepine Oral Suspension USP, 300 mg/5 mL, 250 mL bottle label from Epic Pharma, LLC. The label includes dosage information, storage instructions, and a pharmacist advisory to dispense the Medication Guide separately to each patient. The label states the product is Rx only and includes a barcode and product NDC 42806-600-22.*

FDA Label Image

Principal Display Panel (300 mg/5 mL carton)

Label for Oxcarbazepine Oral Suspension, USP 300 mg/5 mL, 250 mL bottle, by Epic Pharma, LLC. The label includes dosing instructions to shake well before using, storage conditions, and pharmacist dispensing notes. Distributed by Epic Pharma, made in Canada, with NDC 42806-600-22. Bar code and usage warnings are also visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.